Beside its activity of biological reagents commercialization developed and manufactured in its premises, GERME S.A. makes available to pharmaceutical industries its Research and Development structure and its technological platform, for sub-contracting or studies agreements.
Its fields of intervention are particularly the followings:
- Selection of innovative biological reagents
From numerous plant sources, marine sources, from its internal culture collection of micro-organisms or microbial strains isolated for the needs of study, GERME S.A. can select the best production source of a targeted biological molecule (enzyme, enzyme inhibitor, non enzymatic protein, etc.).
These molecules can correspond to an active medicinal ingredient or a diagnostic reagent implemented in a dosage package, in an enzymatic or immuno-enzymatic kit, in a bio-sensor, etc.
- Development in laboratory stage or process pilot stage of biological reagents
The technological platform of GERME S.A. enables to develop extraction and purification processes using systems of crushing, pressing, microfiltration, centrifugation, ultrafiltration, diafiltration, chromatography (gel filtration, affinity, ionic exchange, …) and freeze-drying. The feasibility study consisting of establishing purification techniques defines yields outputs and economical assessment of the selected process.
- Extrapolation and development of laboratory processes for obtaining biological products for pharmaceutical uses
Some pharmaceutical companies agreed with GERME S.A. to develop a purification process finalized at laboratory scale, in order to define the industrial capability of manufacturing project of pharmaceutical molecules. This is the way that molecules with therapeutic uses has been purified at industrial pilot scale.
- Extraction and purification at aqueous phase of customized biological molecules
- Development of methodologies for biochemical dosages
GERME S.A. can define in its laboratories methodologies for biological molecules dosage in liquid or solid systems (solution, tablet, prosthesis, …).
Quite a few single-use sterile medical products (surgical implants, prosthesis, examining gloves, small tools, …) are controlled in our laboratories according to European or US pharmacopoeia.
The company GERME S.A. has founded with the French laboratory of interfacial enzymology and lipolysis physiology (EIPL) of the National Center of Scientific Research (CNRS) a structure aimed at offering to industries and research laboratories a unique know-how on the study of lipolysis: the collaborative laboratory EIPL-GERME S.A.